five year update on adaura clinical trial of tagrisso in egfr early stage nsclc.
Published 1 year ago • 48 plays • Length 4:10Download video MP4
Download video MP3
Similar videos
-
2:06
adaura trial: osimertinib for early stage egfr nsclc - 2022 program: targeted therapies forum
-
5:12
adaura trial: tagrisso & resectable egfr - leading developments & current questions in lung cancer
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
6:23
adaura trial; early stage non–small cell lung cancer
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
3:55
chrysalis trial update in nsclc
-
3:13
updates from adaura: continued dfs benefit with osimertinib vs. placebo
-
1:46
osimertinib after surgery significantly improves survival in resected egfr-mutated nsclc
-
2:16
dr. rotow on results of a phase 1/2 trial with osimertinib/gefitinib in egfr-mutant nsclc
-
5:08
ground-breaking data: phase 3 adaura trial
-
5:18
jill feldman ma med discussing the adaura trial
-
6:55
case 4: treating egfr nsclc after osimertinib
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
4:25
adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
-
11:37
asco23 - lba3: os analysis from the adaura trial of adjuvant osimertinib in resected egfr‐mutate...